Covid/corona and the flu are still out there, still very much out there.I don't feel not well. The cough is just annoying and my wife talks nonsense about it being my cold- yeah a cough that occurs mainly just before sleep and some days on other times. That doesn't fit a sickness at all. I don't want to forced to stand outside the doctors because their medicine is controlled by city hall.
Given the Covid vaccines don't work and quickly becomes contraproductive espcially these these especailly useless boosters- your point is. Vaccine booths are totally empty. By the way my local seven-eleven convience store has removed the silly barrier between seats. You can as always walk the store right next to anyone. A Lawson convience store never had barriers,Covid/corona and the flu are still out there, still very much out there.
It's not you, nothing against you personally. (of course you're one of the the good/rational people, who can diagnose themselves...) If you have any of the symptoms common to either the flu or corona, it's simply good medical practice to be cautious--to take precautions that are both simple and effective.
Medicine is not controlled by city hall. (some of the purse strings, perhaps, but not what doctors may do or decide)
Oh, and to make sure, you've gotten both your latest covid vaccination, and flu shot?
There is a lot of research on the effectiveness of COVID-19 booster vaccines, which are additional doses of vaccine given after the initial vaccination to increase the immune response and protection against the virus. Here are some of the main findings from the web search results:Given the Covid vaccines don't work and quickly becomes contraproductive espcially these these especailly useless boosters- your point is. Vaccine booths are totally empty. By the way my local seven-eleven convience store has removed the silly barrier between seats. You can as always walk the store right next to anyone. A Lawson convience store never had barriers,
I got the latest booster in October. I felt a little more tired than usual but otherwise didn't notice anything. None of the vaccines affected me too much.Yeah, America really went off the conspiracy rails during 2020-2021. Spent so much energy and resources getting the pharmaceutical companies to develop a vaccine for this strange, and unpredictable virus that was running rampant around the world. And then, through the miracle of science, we got a vaccine, and America lost its mind.
Let me know how the booster goes, Frank. I haven't gotten it yet. The other boosters knocked me down for a day.
Well, the last one was only half a day, because my wife was yelling at me, "are you still in bed???"
Even if a patient has been infected with the flu once, they must not let their guard down, as infection with Type A flu doesn't lower the risk of contracting Type B. "Even if you've been infected once, there still are ample benefits to getting vaccinated (against the flu)," Ohashi advises. Japan has been gripped by the extraordinary outbreak of seasonal flu since early September, with average patient numbers rising to 11.07 per medical institution in October, surpassing the 10-patient per institution criterion for local government warnings at an unprecedented pace. According to the health ministry, the average flu patient numbers per institution hit 21.66 between Nov. 13 and 19. Many elementary and junior high schools have been forced to cancel classes due to the virus' rapid spread.
I just left the clinic for ear, nose and throat. Never has anything here taken down like what I caught. Did the camera through the nose. There seems to be a bacterial infection and a problem mucus build-up. Been coughing since last Wednesday. Temperature was 36.4 so that was fine. Well, hopefully I'll recover in about 5 days, if now, back to the clinic.
And I feel for you. I've always had a dry cough over the years, but this was unusual that every 5 minutes during sleep, I 'd have spit. I actually couldn't sleep for 3 days. Thursday was a holiday so Friday I zipped over to the doctor. Fine treatment, but the pharmacy, I definitely went to the wrong place for its helpfulness, but that's another story. Anyway, still coughing which is not good for the brain.Same here. I've been knocked out since the beginning of this week: no fever, but the same mucus build-up you described. I had to cancel a lot of work.
「腹八分目に医者いらず(Harahachibunme ni ishairazu)」=Moderate eating keeps the doctor awayAnd I feel for you. I've always had a dry cough over the years, but this was unusual that every 5 minutes during sleep, I 'd have spit. I actually couldn't sleep for 3 days. Thursday was a holiday so Friday I zipped over to the doctor. Fine treatment, but the pharmacy, I definitely went to the wrong place for its helpfulness, but that's another story. Anyway, still coughing which is not good for the brain.
Take care, Thomas.
I don't know if this will help, but I read that one should only eat about 80% max and keep the tummy not full. Do you know anything about that?
Daiichi Sankyo has reached an agreement with Japan's Ministry of Health, Labour and Welfare (MHLW) to supply the omicron XBB.1.5- adapted monovalent mRNA vaccine (DS-5670) against COVID-19. DS-5670 will be used in the current special temporary vaccination programme against COVID-19 in Japan that began in Autumn 2023. This agreement was concluded to supply 1.4 million doses in FY2023 under the condition that MHLW should grant regulatory approval for DS-5670. Daiichi Sankyo submitted a supplemental New Drug Application (sNDA) for DS-5670 to the MHLW in September 2023. Daiichi Sankyo is now preparing its production facilities to supply DS-5670, the first Japan-made COVID-19 mRNA vaccine, within this year. The company will strive to strengthen technologies for vaccine development and production further, thereby contributing to the safety and security of society and people's health in Japan. DS-5670 is an mRNA vaccine against COVID-19 designed to produce antibodies against the receptor binding domain (RBD) of the spike protein of the novel coronavirus, utilising a novel nucleic acid drug delivery system discovered by Daiichi Sankyo. In Japan, DS-5670, an original-strain-containing monovalent mRNA vaccine, was approved for manufacturing and marketing in August 2023 and is authorised to be used as a booster dose with an indication of "Prevention of disease caused by SARS-CoV-2 infection."
Among the substances produced by the body's immune system, the research team focused on a "secretory antibody" produced on the mucosal surface of the nasal cavity. It is a type of antibody produced by immune cells and plays a role in efficiently eliminating harmful foreign substances that enter the body through the mucous membrane of the nasal cavity. On the other hand, when virus that has multiplied in the body of an infected person leaves the body, it also passes through the mucous membrane of the nasal cavity. It had been thought that the antibody had some kind of effect here, but the details were unknown. Using data on the level of virus particles in 122 people in Japan who were infected with the omicron strain, the researchers examined the secretory antibody and the period of time during which infectious virus particles were shed.
A nonMRNA vaccine is availble called Novavax which I uave heard causes less impact or knocking down. Neigther pfizer or moderna did much to me, I had pfizer this year. covid when I had it last year dec drug on for a month.Let me know how the booster goes, Frank. I haven't gotten it yet. The other boosters knocked me down for a day.
Well, the last one was only half a day, because my wife was yelling at me, "are you still in bed???"
The JN.1 is a mutation of the omicron BA.2 variant, which became mainstream during the pandemic in 2022. JN.1 has been spreading worldwide since around November 2023, and the World Health Organization (WHO) designated it a "variant of interest (VOI)" in December. According to Japan's National Institute of Infectious Diseases, the percentage of JN.1 variant detected among COVID-19 patients increased from just over 10% in the first week of December 2023 to a little over 30% about three weeks later -- and is believed to be significantly increasing. But until now, the detailed characteristics of the new strain were unknown. The team used data from epidemiological studies of viral genomes from the U.K., France and Spain, and used cultured cells for their research. The results showed that JN.1's "effective reproductive number," indicating how many people one infected patient can spread the virus to, is around 1.2 to 1.4 times that of the currently prevalent strain.
The average among the roughly 5,000 medical institutions stood at 16.15 in the week through last Sunday, with the total number of patients they reported up 8 percent from the previous week to 79,605, the data showed. Ishikawa Prefecture in central Japan saw the highest rise among the 47 prefectures with an average of 24.52 patients per institution, despite some reports not being included due to the disastrous impact of an earthquake on New Year's Day. Ishikawa and 40 other prefectures, including Tokyo, logged rises in the most recent week, and averages were also high in Fukushima at 24.49 patients per institution and Aichi at 22.55. Okinawa Prefecture saw the lowest figure at 8.94, followed by Osaka at 9.36 and Aomori at 10.75. New hospitalizations reported from approximately 500 medical institutions nationwide increased 4 percent from the previous week to 3,459.
COVID-19 was downgraded to a lower-risk category that also includes flu under the infectious disease control law in May 2023, and the health ministry currently estimates the infection situation for both COVID-19 and flu based on new cases reported regularly from about 5,000 medical institutions across the country. According to the data, new COVID-19 cases reported in the week to Feb. 11 stood at 13.75 per institution. By prefecture, Ishikawa in central Japan had the largest number, at 21.91, followed by Aichi, also central Japan, at 20.06. Although new cases across Japan dropped on average for the first time in about three months, the country is in a situation that can be called "the 10th wave" of infections, experts warned.
By prefecture, Ishikawa in central Japan had the largest number, at 21.91, ...
Among the various types of vaccinations, there are "regular vaccinations" carried out by municipal governments based on the law, covering 17 illnesses including rubella, tuberculosis and hepatitis B, and "special temporary vaccinations" including inoculations against COVID-19, which remained in this category until March. Cities, towns and villages keep data on these inoculations in "vaccine registers" which include the person's name and address, their date of birth, and the day they were vaccinated, among other information, in digital and other formats.
The situation in Okinawa's medical institutions is critical. Since the end of the Golden Week holiday in May, patient numbers have steadily increased. In June, cases requiring hospitalization also rose. The lack of available beds has led to situations where emergency transport for fever patients, including COVID-19 cases, had to be refused. This situation is impacting non-COVID patients as well. In this hospital footage, you can see the current state of the medical field. A patient with a high fever and suspected COVID-19 could not be admitted due to a lack of available beds. The hospital also faces a shortage of ambulances, leading to a significant increase in the use of doctor cars since June. Doctors noted a change in public awareness toward COVID-19. They mentioned that there has been a decline in concern and preventive measures. The current period also presents challenges in distinguishing COVID-19 from heatstroke, as both cause similar symptoms such as fever, fatigue, headaches, and muscle pain.
Introducing modified killer T cells from donors risks an immunological rejection by the host's body. Kawamoto's team uses killer T cells produced from genetically modified embryonic stem cells, making them less likely to trigger immune system rejection. In a simulated lab setting, Kawamoto's team tested the grown killer T cells on lung cells genetically modified to express COVID markers. The T cells were able to destroy a large majority of the "infected" lung cells within 12 hours. The team opted not to use induced pluripotent stem cells, or iPS cells, developed by a different Kyoto University team.